Literature DB >> 7906038

Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety.

M A Gallo1, S S Smith.   

Abstract

The purpose of this study was to determine whether withdrawal from chronic exposure to the female sex steroid progesterone (P) alters response of female rats to an electrified prod using the defensive burying paradigm, considered a rat model of anxiety. Withdrawal from chronic exposure to 500 micrograms P (daily, SC, for four days) resulted in a significant decrease in the latency (77%, P < 0.05) to prod burial and an increase in duration (75%, P < 0.05) of this reflexive response, compared with the behavior of oil-injected controls. These results are consistent with the idea that withdrawal from chronic exposure to P increases behaviors that accompany anxiety. At a lower dose (50 micrograms), withdrawal from chronically administered P produced significant changes in response to this paradigm only when the steroid was given concomitantly with estradiol (2 micrograms, SC, for two days). Prior exposure to indomethacin, which blocks the conversion of P to its metabolite 3 alpha,5 alpha-tetrahydroprogesterone (3-alpha-hydroxy-5-alpha-pregnan-20-one), prevented P withdrawal from altering response in the defensive burying paradigm. This finding suggests that it may be withdrawal from this metabolite, rather than P, which increases behaviors associated with increased anxiety.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906038     DOI: 10.1016/0091-3057(93)90219-j

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  22 in total

1.  Testosterone increases analgesia, anxiolysis, and cognitive performance of male rats.

Authors:  C A Frye; A M Seliga
Journal:  Cogn Affect Behav Neurosci       Date:  2001-12       Impact factor: 3.282

2.  Inhibiting progesterone metabolism in the hippocampus of rats in behavioral estrus decreases anxiolytic behaviors and enhances exploratory and antinociceptive behaviors.

Authors:  M E Rhodes; C A Frye
Journal:  Cogn Affect Behav Neurosci       Date:  2001-09       Impact factor: 3.282

3.  Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability.

Authors:  Ethan H Beckley; Angela C Scibelli; Deborah A Finn
Journal:  Psychoneuroendocrinology       Date:  2010-12-15       Impact factor: 4.905

4.  Low doses of cocaine decrease, and high doses increase, anxiety-like behavior and brain progestogen levels among intact rats.

Authors:  Amy S Kohtz; Jason J Paris; Cheryl A Frye
Journal:  Horm Behav       Date:  2010-02-19       Impact factor: 3.587

Review 5.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

6.  Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder.

Authors:  Sheryl S Smith; Yevgeniy Ruderman; Cheryl Frye; Gregg Homanics; Maoli Yuan
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Effects of a low dose of ethanol in an animal model of premenstrual anxiety.

Authors:  Sheryl S Smith; Yevgeniy Ruderman; Qi Hua Gong; Maria Gulinello
Journal:  Alcohol       Date:  2004-05       Impact factor: 2.405

8.  Altered levels of sex and stress steroid hormones assessed daily over a 28-day cycle in early abstinent cocaine-dependent females.

Authors:  Helen C Fox; Kwangik A Hong; Prashni Paliwal; Peter T Morgan; Rajita Sinha
Journal:  Psychopharmacology (Berl)       Date:  2007-09-21       Impact factor: 4.530

9.  Nociceptive and anxiety-like behavior in reproductively competent and reproductively senescent middle-aged rats.

Authors:  Alicia A Walf; Jason J Paris; Cheryl A Frye
Journal:  Gend Med       Date:  2009

Review 10.  Neurosteroids in the context of stress: implications for depressive disorders.

Authors:  Susan S Girdler; Rebecca Klatzkin
Journal:  Pharmacol Ther       Date:  2007-05-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.